# Gynecomastia

Evaluate gynecomastia by separating typical pubertal or drug-related disease from hypogonadism, systemic illness, hormone-secreting tumors, and male breast cancer. Focus testing on atypical, progressive, or unexplained presentations; withdraw reversible exposures and reserve surgery for persistent, consequential disease.

**Clinical question:** How should clinicians evaluate gynecomastia, identify secondary causes, and select observation, cause-directed treatment, or surgery?

Updated: 2026-09-16T00:19:17.480889+00:00

## What matters in practice
- Typical pubertal gynecomastia usually requires reassurance and follow-up rather than routine endocrine testing; 85% to 90% regress within 6 months to 2 years. [19][22]
- A focused medication, supplement, anabolic-androgenic steroid, recreational substance, systemic-disease, breast, and testicular assessment determines whether laboratory testing is needed. [7][20][21]
- For unexplained, recent-onset, progressive, painful, or otherwise atypical gynecomastia, obtain testosterone, LH, FSH, estradiol, beta-hCG, prolactin, thyroid testing, renal function, and liver tests; add DHEA-S when an adrenal tumor is a concern. [20][21]
- Do not order imaging routinely; use testicular ultrasonography, breast imaging with biopsy, adrenal imaging, or pituitary MRI only when examination or laboratory findings direct the anatomic search. [12][20]
- Stop or replace an implicated medication or exposure when feasible; long-standing gynecomastia is less likely to regress because glandular tissue becomes fibrotic. [19][20]
- Consider surgery for persistent gynecomastia with substantial pain, psychosocial burden, cosmetic concern, or suspected malignancy; defer elective adolescent surgery until pubertal completion to reduce regrowth risk. [19]

## Which gynecomastia presentations need urgent exclusion of malignancy or endocrine disease?

Begin with phenotype and tempo before ordering a broad endocrine panel.

Document onset, progression, laterality, tenderness, nipple discharge, sexual function, change in virilization, weight change, hyperthyroid symptoms, and recent recovery from malnutrition or serious illness. Review prescription and nonprescription agents, supplements and herbal products, cosmetic exposures, cannabis and other recreational substances, and anabolic-androgenic steroid use. Also ask about renal disease, liver disease, thyroid disease, infertility, and family or syndromic features suggesting Klinefelter syndrome. [7][12][20][21]

Examine whether enlargement is palpable subareolar glandular tissue versus predominantly adiposity, then assess regional lymph nodes, skin and nipple findings, thyroid, abdomen for hepatomegaly or mass, body hair and other virilization, and both testes for volume asymmetry, atrophy, or a discrete mass. A breast mass suspicious for malignancy requires mammography and biopsy rather than empiric hormonal therapy. [12][20]

Recent, prominent, painful, progressive, or otherwise unexplained enlargement warrants directed evaluation because it can signal drug exposure, gonadal failure, altered estrogen production, renal or hepatic disease, thyrotoxicosis, or a tumor. Conversely, an adolescent with otherwise typical pubertal development, a reassuring breast and testicular examination, and no concerning history generally does not need routine hormonal testing. [7][21][22]
- Escalate promptly for a suspicious breast lesion or regional adenopathy: obtain mammography and tissue diagnosis. [12][20]
- Escalate for a palpable testicular lesion, testicular atrophy, or biochemical evidence of hCG/estradiol excess or gonadotropin abnormality: obtain testicular ultrasonography. [10][20]
- Do not assume unilateral enlargement is malignant; unilateral and bilateral gynecomastia both occur, but physical findings determine whether breast cancer evaluation is necessary. [24]

*Phenotype-based initial branch points in gynecomastia evaluation. [7][12][20][21][22]*

| Clinical pattern | Immediate next action | What the result changes |
| --- | --- | --- |
| Typical pubertal presentation with normal examination and no concerning exposure or systemic features | Reassure and observe; avoid routine endocrine testing. [7][22] | Most cases regress during follow-up; investigate only if course or examination becomes atypical. [19] |
| Recent, progressive, painful, prominent, or unexplained enlargement | Obtain directed hormonal and systemic laboratory evaluation. [20][21] | Identifies hypogonadism, thyroid, renal, hepatic, adrenal, or tumor-associated pathways requiring cause-directed management. [20] |
| Suspicious breast examination | Mammography and biopsy. [12][20] | Establishes or excludes breast malignancy before nonoperative management. |
| Testicular mass, atrophy, or abnormal hCG, estradiol, or gonadotropins | Testicular ultrasonography. [10][20] | Directs evaluation for testicular pathology or altered gonadal function. |

## Which laboratory tests are indicated, and how should results direct imaging?

Test selectively when history or examination does not identify a benign physiologic or exposure-related explanation.

For recent-onset or unexplained gynecomastia, measure serum total and free or bioavailable testosterone, LH, FSH, estradiol, beta-hCG, prolactin, thyroid-stimulating hormone with free thyroxine, serum creatinine, and liver enzymes. Add DHEA-S or urinary 17-ketosteroids when a feminizing adrenal tumor is in the differential. These tests distinguish androgen deficiency, altered gonadotropin signaling, hCG- or estradiol-associated tumor physiology, hyperprolactinemia, thyrotoxicosis, and renal or hepatic contributors. [20][21]

Interpret hormone results as a pattern rather than in isolation. Low testosterone with altered LH and FSH supports evaluation for hypogonadism; elevated beta-hCG or estradiol, or depressed LH in an otherwise unexplained presentation, should prompt testicular ultrasonography. If testicular ultrasonography is normal despite these abnormalities, proceed to chest radiography and abdominal CT to search for an extratesticular or adrenal source. [10][12]

Reserve pituitary MRI for a laboratory or clinical pattern that localizes to the sella, rather than using it as routine imaging. Similarly, adrenal CT should follow clinical or biochemical concern for an adrenal mass. Routine imaging without examination or laboratory triggers is not recommended. [20]
- Order karyotype testing when the examination or clinical context raises concern for Klinefelter syndrome. [10]
- If infertility is a major concern in a patient with suspected hypogonadism, include seminal fluid analysis in the reproductive assessment. [12]
- In adolescents, routine endocrine panels have low yield: endocrine investigations provided no new clinical information in 99.4% of cases in one 197-patient series. [22]

*Targeted tests and downstream actions for unexplained or atypical gynecomastia. [10][12][20][21]*

| Test or finding | Etiologic branch | Next action |
| --- | --- | --- |
| Total/free testosterone with LH and FSH | Androgen deficiency or abnormal gonadotropin signaling. [12][20] | Evaluate the hypogonadal pattern and its cause; assess fertility when relevant. [12] |
| Beta-hCG or estradiol elevation; depressed LH | Possible testicular or extratesticular hormone-secreting process. [10][12] | Perform testicular ultrasonography; if normal, obtain chest radiography and abdominal CT. [10] |
| TSH and free thyroxine abnormality | Thyroid hormone excess or other thyroid dysfunction. [20][21] | Treat or further evaluate thyroid disease as the reversible contributor. [20] |
| Elevated creatinine or liver enzymes | Renal or hepatic disease. [20][21] | Evaluate and manage underlying systemic disease. [20] |
| DHEA-S or urinary 17-ketosteroid abnormality when adrenal tumor suspected | Feminizing adrenal tumor pathway. [20] | Proceed to adrenal imaging directed by the clinical and biochemical presentation. [20] |
| Suspicious breast mass | Male breast cancer pathway. [12][20] | Mammography and biopsy. [12][20] |

## How should treatment be matched to the etiologic branch and duration?

Remove reversible drivers first; observation is appropriate when symptoms and malignancy risk are low.

When a medication, supplement, estrogen-containing exposure, recreational substance, or anabolic-androgenic steroid is implicated, discontinue, replace, or stop the exposure when clinically feasible and reassess the breast examination and symptoms. Drug-induced gynecomastia may regress after withdrawal, but prolonged disease is less likely to resolve completely after fibrotic change develops. [7][16][19][20]

Treat identified systemic and endocrine causes rather than treating breast enlargement in isolation. Relevant branches include hypogonadism, thyrotoxicosis, renal or hepatic dysfunction, hyperprolactinemia, and testicular, adrenal, or other malignancy-associated hormone production. The diagnostic pattern should determine the referral and definitive therapy rather than a uniform antiestrogen strategy. [12][20][21]

For asymptomatic, long-standing adult gynecomastia without concerning findings, reassurance is appropriate. For new-onset disease, follow-up is reasonable because spontaneous regression occurs in adolescents and adults, whereas persistence beyond 1 year is associated with a low likelihood of complete regression. [19]

Do not combine anastrozole with tamoxifen: coadministration lowers anastrozole concentration and provided no efficacy benefit over tamoxifen in breast cancer trial data. Anastrozole has not demonstrated efficacy for pubertal gynecomastia and is not an established treatment for that indication. [1][2][3][4]
- Document pain, tenderness, psychosocial impact, duration, and objective breast findings at reassessment; these determine whether continued observation remains acceptable or procedural treatment should be discussed. [7][19]
- Avoid treating typical pubertal gynecomastia with surgery or hormones during the first 1 to 2 years. [6]
- Counsel patients using anabolic-androgenic steroids that acne and gynecomastia are frequent adverse effects and that withdrawal effects can create cyclical dependency. [16]

### Adolescent gynecomastia

For physiologic pubertal gynecomastia, reassure, assess psychological distress, and follow clinically. Approximately 85% to 90% of pubertal cases regress between 6 months and 2 years; persistence after age 17 is uncommon. The reported median duration in one longitudinal cohort was 1.9 years. [7][14][19]

Order hormonal testing in adolescents when gynecomastia is excessive, prolonged, occurs outside midpuberty, or is accompanied by concerning examination findings or exposures. The suggested targeted evaluation includes testosterone, estradiol, hCG, LH, FSH, TSH, and DHEAS; additional studies may include prolactin, free thyroxine, inhibin B, and anti-Müllerian hormone when the clinical differential requires them. [14]
- Assess testicular examination carefully; a testicular mass, atrophy, or incomplete/abnormal pubertal development shifts management from observation to endocrine or tumor-directed evaluation. [7][14][20]
- Address distress directly: psychological discomfort is common, and its severity may support referral for persistent disease even when the endocrine evaluation is unrevealing. [7][22]

*Management by duration, impact, and cause. [6][7][16][19][20]*

| Situation | Management | Escalation trigger |
| --- | --- | --- |
| Typical pubertal gynecomastia within 1 to 2 years | Reassurance, psychosocial assessment, and clinical follow-up; avoid hormones or surgery during this interval. [6][7] | Persistence, progression, atypical timing, concerning examination, or significant distress. [7][14] |
| Identifiable drug, supplement, or anabolic steroid exposure | Stop, replace, or discontinue the implicated exposure when feasible. [7][16][20] | Persistent enlargement or pain after exposure removal, or abnormal examination/laboratory findings. [19][20] |
| Systemic/endocrine disorder or hormone-secreting tumor pattern | Treat the underlying disorder and complete directed imaging or specialty evaluation. [10][12][20] | Abnormal beta-hCG, estradiol, gonadotropins, testicular examination, or suspicious breast findings. [10][20] |
| Persistent disease for more than 12 months with substantial symptoms or psychosocial burden | Discuss surgical management after cause evaluation. [19] | Suspected malignancy requires diagnostic tissue evaluation rather than elective cosmetic surgery. [19][20] |

## When should gynecomastia surgery be considered?

Surgery is a definitive option after etiologic evaluation and when persistence or consequences outweigh operative tradeoffs.

Consider surgical treatment for long-standing gynecomastia, generally beyond 12 months, when there is considerable pain, psychological stress, cosmetic concern, or concern for malignancy. Subcutaneous mastectomy is the most commonly used operative technique for glandular tissue; technique selection depends on the relative fat, parenchyma, skin laxity, and severity of enlargement. [19]

In adolescents, defer elective surgery until the testes have reached adult size because breast tissue can regrow if surgery occurs before pubertal completion. Surgery may nevertheless be necessary for a suspicious lesion, in which case diagnostic priorities supersede cosmetic timing. [19]

Liposuction may be used with mammoplasty in men with gynecomastia when body contour and adipose contribution warrant it. In body-contouring data, reported overall liposuction complication rates were 2.4%, including 0.7% for liposuction alone and 3.5% when combined with other procedures; complications include ecchymosis, edema, infection, seroma, hematoma, and venous thromboembolism. These estimates are not specific to gynecomastia operations. [23]
- Before referral, document duration, glandular versus adipose distribution, skin excess, tenderness, psychological impact, prior exposure withdrawal, and completed evaluation for suspicious breast or testicular findings. [19][20]
- Do not use elective surgery as a substitute for evaluation when malignancy is suspected; obtain mammography and biopsy. [12][20]

*Surgical decision points in gynecomastia. [19][23]*

| Candidate feature | Procedural implication | Key tradeoff |
| --- | --- | --- |
| Persistent glandular gynecomastia with pain, distress, or cosmetic burden | Subcutaneous mastectomy is commonly used. [19] | Long-standing fibrotic tissue is less likely to regress spontaneously, supporting definitive treatment when symptoms are consequential. [19] |
| Significant adipose component requiring contouring | Liposuction may be used in conjunction with mammoplasty. [23] | Risks include infection, seroma, hematoma, and venous thromboembolism. [23] |
| Adolescent without completed puberty | Usually defer elective surgery until adult testicular size. [19] | Earlier surgery can be followed by regrowth of breast tissue. [19] |
| Suspicion for breast malignancy | Diagnostic mammography and biopsy take precedence. [12][20] | Cosmetic operative planning should wait for tissue diagnosis. |

## References
1. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use anastrozole tablets safely and effectively. See full prescribing information for anastrozole tablets. Initial U.S. Approval — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c7666def-a855-4ca3-a322-603a88a44101&type=display
2. highlights of prescribing information - DailyMed — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de
3. [PDF] Arimidex (anastrozole) tablet label - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020541s026lbl.Pdf
4. [PDF] 20541Orig1s023 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/review/2018/20541Orig1s023.pdf
5. [PDF] Anastrozole Clinical Pediatric Review - FDA — www.fda.gov — https://www.fda.gov/media/75520/download
6. Gynecomastia in Adolescent Boys - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/332010
7. Gynecomastia in adolescents : Current Opinion in Pediatrics — journals.lww.com — https://journals.lww.com/co-pediatrics/fulltext/2008/08000/gynecomastia_in_adolescents.3.aspx
8. Routine Endocrinologic Evaluation Is Unnecessary... - Ovid — journals.lww.com — https://journals.lww.com/00003094-202463110-00001
9. Gynecomastia : Indian Journal of Endocrinology and Metabolism — journals.lww.com — https://journals.lww.com/indjem/fulltext/2014/18020/gynecomastia__clinical_evaluation_and_management.4.aspx
10. Multidisciplinary Team Care: Adolescent Breast — journals.lww.com — https://journals.lww.com/00078609-202505000-00008
11. Gynecomastia - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/gynecomastia
12. 1 Testosterone - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/1-testosterone
13. Hyperestrogenism - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/hyperestrogenism
14. 11-Ketotestosterone - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/11-ketotestosterone
15. Persistent Gynecomastia due to Short-term Low-dose Finasteride for ... — academic.oup.com — https://academic.oup.com/jcemcr/article/2/5/luae050/7657109
16. Androgen Misuse and Abuse | Endocrine Reviews - Oxford Academic — academic.oup.com — https://academic.oup.com/edrv/article/42/4/457/6117781
17. Effects of Gynecomastia Surgery on Readiness and Return to Duty ... — academic.oup.com — https://academic.oup.com/milmed/article-pdf/189/7-8/e1637/58417516/usad452.pdf
18. Male hypogonadism: recommendations from the Fifth International ... — academic.oup.com — https://academic.oup.com/smr/article/13/4/548/8242145
19. Gynecomastia: Clinical evaluation and management — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3987263
20. [PDF] Gynecomastia - Cleveland Clinic Journal of Medicine — www.ccjm.org — https://www.ccjm.org/content/ccjom/71/6/511.full.pdf
21. [Disordered hormone regulation in gynecomastia] - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/12704923
22. Most Teens with Gynecomastia Don't Need Hormone Lab Tests | ASPS — www.plasticsurgery.org — https://www.plasticsurgery.org/news/press-releases/most-teens-with-gynecomastia-dont-need-hormone-lab-tests
23. Liposuction: Concepts, safety, and techniques in body-contouring surgery | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/87/6/367
24. Clinical and Etiological Aspects of Gynecomastia in Adult Males: A Multicenter Study - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996435

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.